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Abstract
Retinal vein occlusion is a leading cause of visual impairment. Experimental models of this
condition based on laser photocoagulation of retinal veins have been described and exten-
sively exploited in mammals and larger rodents such as the rat. However, few reports exist
on the use of this paradigm in the mouse. The objective of this study was to investigate a
model of branch and central retinal vein occlusion in the mouse and characterize in vivo lon-
gitudinal retinal morphology alterations using spectral domain optical coherence tomogra-
phy. Retinal veins were experimentally occluded using laser photocoagulation after
intravenous application of Rose Bengal, a photo-activator dye enhancing thrombus forma-
tion. Depending on the number of veins occluded, variable amounts of capillary dropout
were seen on fluorescein angiography. Vascular endothelial growth factor levels were
markedly elevated early and peaked at day one. Retinal thickness measurements with
spectral domain optical coherence tomography showed significant swelling (p<0.001) com-
pared to baseline, followed by gradual thinning plateauing two weeks after the experimental
intervention (p<0.001). Histological findings at day seven correlated with spectral domain
optical coherence tomography imaging. The inner layers were predominantly affected by
degeneration with the outer nuclear layer and the photoreceptor outer segments largely pre-
served. The application of this retinal vein occlusion model in the mouse carries several ad-
vantages over its use in other larger species, such as access to a vast range of genetically
modified animals. Retinal changes after experimental retinal vein occlusion in this mouse
model can be non-invasively quantified by spectral domain optical coherence tomography,
and may be used to monitor effects of potential therapeutic interventions.
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Introduction
Retinal vein occlusion (RVO) is a potentially blinding disease affecting an estimated 16,4 mil-
lion people worldwide, and is the most common retinal vascular disease after diabetic retinopa-
thy[1]. RVO can be divided into branch retinal vein occlusion (BRVO) or central retinal vein
occlusion (CRVO). Whereas in CRVO the occlusion occurs at the optic disc affecting all
tributaries of the central retinal vein[2], arterial compression of a branch vein is thought to
lead to thrombus formation in BRVO[3]. Both CRVO and BRVO result in capillary dropout,
and in some cases generalized inner retinal ischemia[4]. Despite the relatively high prevalence
there is substantial controversy surrounding the exact patho-mechanisms occurring in RVO
and some of the presumed risk factors[5]. Whereas anti-vascular endothelial growth factor
treatment has revolutionized the treatment of vascular endothelial growth factor (VEGF) driv-
en macular edema as the main vision threatening sequelae of RVO[6], the causal pathology is
not addressed and intravitreal injections are often required frequently and over long periods of
time. More instrumental but investigational approaches, such as isovolemic hemodilution[7]
or laser-induced chorioretinal venous anastomosis[8], aim at preventing adverse outcomes of
RVO by facilitating reperfusion. However, the effectiveness and clinical relevance of the latter
treatments remain controversial[9]. The optimal treatment of retinal ischemia and the role of
collaterals remain ambiguous[10]. More recent data suggest that inflammation plays an under-
estimated role in the pathogenesis of RVO[11–13]. The significance of inflammatory processes
in the disease pathology can be inferred from the consistent therapeutic effect seen with ocular
corticosteroid treatment[14], but little is known about the dynamics and the role of immune
cells such as microglia or macrophages in the retina in RVO.
Animal models may help answer some of these questions, and thus facilitate the develop-
ment of new treatment modalities for BRVO and CRVO. Whereas experimental RVO has
been reported in the rhesus monkey[15], pig[16], minipig[17], goat[18], cat[19], dog[20], rab-
bit[21] and particularly the rat[22–24], there is little data on RVO in mice[25–27]. This is
mainly due to the small dimensions of the mouse eye with the ensuing difficulties in manipula-
tion. However, as experimental animals mice have several advantages. Transgenic mice offer
unsurpassed possibilities to investigate the role of innate immunity and molecular-biological
cascades during RVO. New imaging techniques such as optical coherence tomography (OCT)
have only recently become available for retinal imaging in small rodents and allow for longitu-
dinal follow-up in individual animals[28,29]. Here, we characterize a mouse model of RVO
using fluorescein angiography (FA) and OCT to quantify retinal changes. Different laser proto-
cols were applied to mimic BRVO and CRVO.
Materials and Methods
Animals
This study was approved by the local Animal Ethics Committee (Veterinärdienst des Kantons
Bern: BE 38/13) and conformed to the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. 53 male BALB/c AnNCrl mice (5–6 weeks old, Charles River Laborato-
ries, Sulzfeld, Germany) were housed under temperature and humidity-controlled conditions
in individually ventilated cages with a 12-hour light/12-hour dark cycle, and were provided
food and water ad libitum. 40 of them were used for OCT follow-up and histology, the remain-
der of mice was included in the retinal VEGF levels analysis. Inhalation anesthesia with isoflur-
ane (Forene, AbbVie AG, Bar, Switzerland) was used for the laser procedures. For OCT and
FA mice were anesthetized by intraperitoneal injection of 1 mg/kg medetomidine (Dormitor
1 mg/mL, Provet AG, Lyssach, Switzerland) and 80 mg/kg ketamine (Ketalar 50mg/ml,
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Parke-Davis, Zurich, Switzerland). Atipamezol (Antisedan 5 mg/mL, Provet AG, Lyssach,
Switzerland) was used to antagonize medetomidine at the end of the intervention. Pupils were
dilated with tropicamide 0,5%/phenylephrine 2,5% eye drops (Hospital Pharmacy, Inselspital,
Bern, Switzerland). At the end of the experiment, mice were euthanized using 100% carbon di-
oxide at a fill rate of about 20% to 30% of the chamber volume per minute. Upon completion
of the procedure, death was confirmed by ascertaining cardiac and respiratory arrest.
Laser induced vein occlusion
RVO was induced by 532 nm laser photocoagulation (Visulas 532s, Carl Zeiss Meditec AG,
Oberkochen, Germany) using a slit lamp adapter (Iridex Corporation, Mountain View, CA)
mounted on a commercially available slit lamp (BM900, Haag-Streit AG, Koeniz, Switzerland)
within 3 minutes after intravenous injection of 0.15 ml rose bengal (4,5,6,7-tetrachloro-
2',4',5',7'-tetraiodo-fluorescein (Sigma-Aldrich Switzerland, Buchs, Switzerland), 5mg/ml sa-
line) into the tail vein, similar to the protocol employed by others[24,27]. One vein was occlud-
ed in the single vein laser group whereas all veins were targeted in the multiple vein laser
group. A small 2 mm fundus laser lens (Ocular Instruments, Inc., Bellevue, WA) was used to
visualize the fundus and blood vessels during the laser treatment. Hydroxypropylmethylcellu-
lose 2% (Methocel, OmniVision AG, Neuhausen, Switzerland) was used as viscous coupling
fluid. The laser settings were 50 μm spot size, 160 mW and 0.8–2.5s. In most eyes several burns
were necessary to achieve occlusion of the retinal vessel. Burns were applied sequentially from
distal to proximal to minimize the risk of iatrogenic vitreous hemorrhage. On average 2–5
burns were applied per vein. Occlusion was deemed complete when whitening of the blood ves-
sel and stasis in its distal parts were observed on direct fundus observation with the laser lens
during the laser procedure. In some animals the central vein occlusion phenotype was noted
on subsequent examinations despite targeting only a single vein, most likely because the laser
burns were placed too close to the optic nerve or variable susceptibility of different batches of
animals. Hence, the final assignment to experimental groups was made based on the phenotype
on FA during follow-up.
Fundus color photography
Vascular occlusion was confirmed and documented immediately after laser application by fun-
dus color photography at different magnifications (Fig. 1C (low magnification), 1D (high mag-
nification)). Images were taken with an ultra-widefield panoramic 200TX device (Optos plc,
Dunfermline, Scotland) without a contact lens, as described elsewhere[30].
Fluorescein angiography
A confocal scanning laser ophthalmoscope (Heidelberg Spectralis HRA+OCT, Heidelberg En-
gineering GmbH, Heidelberg, Germany) was used for FA using a standard 55° lens without
any additional contact lens on the mouse eye. For orientation an infrared image was acquired
before subcutaneous injection of 5μg fluorescein (Fluoresceine 10% Faure 0.5g/5ml, Novartis
Pharma Schweiz AG, Rotkreuz, Switzerland). Consecutive photographs were taken with late
images taken two minutes after the fluorescein injection.
OCT acquisition
Mouse retina OCTs were acquired using the Heidelberg Spectralis HRA+OCT system accord-
ing to the protocol described by Fischer et al. with slight modifications. [31] Briefly, a +4 dpt
rigid gas permeable contact lens (Quantum I, Bausch + Lomb Inc., Rochester, NY) was placed
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on the mouse eye, and a 78D standard ophthalmic non-contact slit lamp lens (Volk Optical
Inc., Ohio, USA) was taped in front of the standard 30° Heidelberg Spectralis optic. The mouse
eye had previously been dilated with tropicamide 0,5%/phenylephrine 2,5% eye drops (Hospi-
tal Pharmacy, Inselspital, Bern, Switzerland) and hydroxypropylmethylcellulose 2% (Methocel,
OmniVision AG, Neuhausen, Switzerland) was used as coupling gel.
Volume scans centered on the optic nerve were acquired using the ‘fast’ preset in the Auto-
matic Real-Time (ART) mode, averaging 9 frames per image. Each volume covered 20° x 20°,
and consisted of 25 horizontal B-scans (512 A-scans each), 240μm apart.
Retinal thickness measurements using OCT images
The main purpose of OCT imaging was quantification of the total retinal thickness. In the first
instance the Heidelberg Eye Explorer (Version 1.7.1.0, Heidelberg Engineering GmbH, Heidel-
berg, Germany) segmentation algorithm was applied, which recognizes the internal limiting
membrane and the basal membrane. Placement of the segmentation lines was checked on all
OCT scans by experienced OCT readers (AE, CD). The software reliably identified the internal
limiting membrane and manual correction was rarely required here. However, in most eyes the
basal membrane segmentation line was placed on the sclera. It was therefore necessary to
Fig 1. Experimental retinal vein occlusion in mice. (A) Location of experimental vein thrombosis. (B)
Confirmation using ultra-widefield retinal imaging three days after occlusion. The vein appears dilated distally
with reduced blood vessel caliber proximal to the intervention site. (C&D) Color retinal imaging using ultra-
widefield technology illustrating the situation immediately after application of the laser burn. The veins appear
white at the occlusion site and stasis of the blood column is observed. (C: overview,D: laser site at higher
magnification).
doi:10.1371/journal.pone.0119046.g001
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manually reposition this segmentation line after visual identification of the basal membrane on
almost all scans.
For analysis of the retinal thickness a standard ETDRS grid with circle diameters 1mm,
3mm, and 6mm was centered on the optic nerve head. Retinal thickness measurements dis-
played for the inner ring were recorded in each quadrant (superior, anterior, inferior, posteri-
or). This data was then used for statistical analysis. Of note, lateral measurements are not
accurate since the dimensions of the mouse eye differ significantly from a human eye. Howev-
er, axial OCT measurements seem fairly accurate[32].
Histology
Retinas from experimental animals were examined histologically seven days after laser induced
RVO. The eyes were removed from killed animals and fixed for at least 24 hours in 10% buff-
ered formalin. A corneal suture was used to define the orientation of the eye and identify the la-
sered area of the retina. Samples were then processed for routine paraffin embedding and 4 μm
sections containing the optic nerve head were cut. After deparaffinization, sections were
stained with hematoxylin & eosin and permanently mounted. The cell density in the ganglion
cell layer was estimated by manually counting the cell nuclei in this layer per unit of length
from ora serrata to ora serrata (S1 Fig.). The average inner nuclear layer thickness was approxi-
mated in a similar way: Briefly, the area comprising the inner nuclear layer on histology sec-
tions was measured using imaging analysis software (ImageJ for Mac OS X version 1.48,
National Institute of Health, Bethesda, MD) and then divided by the length of the assessed reti-
nal area. The parts of the retina with signs of collateral damage in the outer layers at the laser
site were not included in this quantification.
VEGF Immunoassay
Retinal VEGF levels after experimental vein occlusion were analyzed by the mouse VEGF
Quantikine ELISA immunoassay (R&D Systems, Inc., Minneapolis, MN) according to manu-
facturer's instructions. Briefly, experimental and control contralateral retinas were isolated at
the 1 and 3 day time points. Retinas were triturated in 200 μl phosphate-buffered saline using a
polytron for 20 seconds at level 3. The retina suspensions were then centrifuged at 5000 g for 5
minutes. Supernatants were diluted 1:4 using the RD5T diluent from the kit and assayed for
VEGF quantification. Absorbance was read for each sample at 450 nm wavelength with refer-
ence to 570 nm wavelength using an Infinite M1000 PRO microplate reader (Tecan Group
Ltd., Maennedorf, Switzerland). Blank reads were subtracted from the corrected 450 nm reads
and a standard curve was generated according to the dilutions of the standard sample (Sf 21-ex-
pressed recombinant mouse VEGF164) provided by the kit.
Statistics
Results are presented as mean ± SEM. For statistical analysis of retinal thickness on OCT a
one-way ANOVA followed by a Tukey’s multiple comparisons test was performed. To assure
independence of samples the analysis was conducted for right and left eyes separately because
both eyes were included in the study from some animals. A two-way ANOVA with Tukey’s
multiple comparisons test was used to analyze VEGF data. For this experiment only one eye
per animal had been laser treated and the contralateral eye served as control. The significance
level was set at alpha = 0.05. Statistical data analysis was performed using GraphPad Prism ver-
sion 6 for Mac OS X (GraphPad Software Inc, La Jolla, California, USA).
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Results
57 eyes of 31 mice with bilateral experimental retinal vein occlusion were included for imaging
and OCT analysis. 25 eyes had one vein occluded, 32 eyes presented with the central retinal
vein occlusion phenotype, and 18 eyes were used as controls. The occurrence of vitreous hem-
orrhages (n = 4) was the most common reason that eyes had to be excluded from final analysis.
Another 26 eyes of 13 animals with unilateral experimental retinal vein occlusion were includ-
ed for retinal VEGF analysis, the contralateral eye serving as control.
Fluorescein angiography
FA showed clearly distinct areas of capillary non-perfusion distal to the occlusion site. The dif-
ferent laser patterns resulted in two distinctly different phenotypes: Firstly, sectoral capillary
drop out to a variable degree was induced by laser application to a single vein about one to two
disc diameters from the optic nerve (Fig. 1). The amount of capillary dropout ranged from dis-
crete changes on FA (Fig. 1B) to more discernible sectoral capillary loss (Fig. 2B). Second, oc-
clusion of all retinal veins around the optic nerve head caused more widespread breakdown of
capillaries (Fig. 2D) resembling CRVO in humans. No retinal neovascularizations were de-
tected on FA in any eyes during the observational period of up to four weeks.
Histological changes
The histological analysis of eyes with experimentally occluded veins revealed changes, which
corroborate the presence of inner retina hypoxia in the sectors affected by venous stasis. The
main feature was thinning of the inner two thirds of the retina (Fig. 3A and 3E). All inner reti-
nal layers were affected. The cell density in the ganglion cell layer was reduced (p<0.0001).
Thinning of the inner plexiform layer was evident. Likewise, the number of nuclei in the inner
nuclear layer was diminished (p<0.0001; S1 Fig.). The outer plexiform layer was completely
absent in the more posterior parts of the retina. Interestingly, this layer seemed to be more pre-
served adjacent to the ora serrata (Fig. 3B and 3F). All these changes appeared slightly more ob-
vious in eyes that had had laser to multiple veins (Fig. 3E).
Collateral damage affecting the photoreceptors was evident in areas adjacent to the laser
spots (Fig. 3A and 3E). Additionally, in these zones subretinal lesions (Fig. 3D) were found that
had a similar appearance to those described by Chidlow et al. after laser application to the reti-
na[33]. Structural changes were particularly marked in eyes after laser to multiple veins
(Fig. 3E).
Cellular elements were also found in the vitreous (Fig. 3A and 3E). They were scattered in
the vitreous cavity, and cell density seemed to be more marked neighboring the ora serrata
(Fig. 3A, left part of the microphotograph) and the optic nerve head (Fig. 3E). Cellular infiltra-
tion of the area above the optic nerve head was particularly evident in eyes that had severe is-
chemic changes on FA and OCT (Fig. 4K–4M).
OCT changes
Retinal thickness changes over time were analyzed using the OCT imaging data. For the eyes
with single vein laser, the retinal thickness in the treated quadrant had increased significantly
(Fig. 4A: BRVO) on day 3. However, at subsequent time points from day 7 onwards the
thickness of the retina steadily decreased, and was significantly thinner than in control eyes
(218±3.2μm). Interestingly, although there was initial thickening, intraretinal cysts were not
observed. In eyes that had occlusion of multiple veins, similarly, a significant increase in retinal
thickness was observed on day 3 after laser occlusion (Fig. 4A: CRVO). However, the diffuse
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Fig 2. Angiographic findings with different laser patterns seven days after experimental retinal vein
occlusion. (A) High-resolution fluorescein angiogram (Heidelberg Spectralis HRA) displays the structure of
the blood vessels at the level of the capillaries in a control mouse. (B-D) Images represent the distinct
angiographic patterns after different types of laser application. (B) Successful experimental retinal vein
occlusion of a single vessel with blood flow still absent proximal to the interventional site. Some drop out of
capillaries in the drainage area of the affected vein is observed, which is particularly marked adjacent to the
laser site. (C) In some experimental eyes the arterial side of the circulation is affected too, and a complete
breakdown of capillary perfusion is manifest in a sector of the retina. (D) In an experimental animal, which had
all veins occluded, capillary drop out is more widespread and affects all quadrants to a similar extent. Some
veins show reperfusion.
doi:10.1371/journal.pone.0119046.g002
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Fig 3. Correlation of angiographic findings with histology seven days after laser photocoagulation. Representative images after (A-D) single vein
occlusion, (E-G) multiple vein occlusion, and (H-J) a control eye. (A, E, H) Whole eye hematoxylin & eosin sections [scale bars 500 μm], (B, F, I) magnified
cutouts of the peripheral retina [scale bars 150 μm], and (C,G, J) fluorescein angiograms. At the laser site destruction of the outer retinal layers is evident
(insetD) with a subretinal scar-like lesion (black arrows), representing collateral damage. (E) These changes are more pronounced in eyes where all veins
have been occluded. (B, F) Interestingly, the inner retinal layers distal to the interventional site are thinner than in the control (I), whereas the outer nuclear
layer and the photoreceptor outer segments are of normal dimensions. The outer plexiform layer is partially missing. The cell density in the ganglion cell layer
is reduced in eyes after laser to (F) multiple veins and after (B) single vein laser in the affected area of the retina.
doi:10.1371/journal.pone.0119046.g003
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Fig 4. Optical coherence tomography and thicknessmeasurements. (A) Mean total retinal thickness
(means±SEM) over 4 weeks. The retinal thickening is marginally greater after occlusion of all retinal veins
(CRVO) than after blockage of a single vein (BRVO) up to about day 7 (* p = 0.0426). At later time points the
retinal thickness is decreased in the affected areas after both CRVO and BRVO, but there is no longer a
statistical difference between the two laser patterns. The mean retinal thickness in affected quadrants is
significantly different (p< 0.001) from control eyes (grey line) at all time points except day 7. (B-H) BRVO
phenotype after occlusion of a single vein. (C) Fluorescein angiogram. (D-H) Serial scans taken at the
location highlighted on photograph (B). The red arrowhead marks a retinal artery at the right border of the
catchment area of the occluded vein. (I-O) CRVO phenotype after occlusion of multiple veins. (J) Fluorescein
OCT Findings in Experimental Retinal Vein Occlusion in the Mouse
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retinal edema quickly resolved thereafter, and by day 7 the retinal thickness was back to almost
normal values. Subsequently, retinal thinning was noted to a similar extent as in eyes with a
single occluded vein. In areas with impaired perfusion the structural features of the retina
vanished and the retina appeared hyperreflective on OCT (Fig. 4D, left from the red arrow;
Fig. 4K, 4L). Besides the sporadic occurrence of some cellular infiltration of the vitreous above
the optic nerve head (Fig. 4K–4M) small amounts of subretinal exudative fluid were occasion-
ally detected (Fig. 4F, yellow arrows).
Reperfusion patterns in longitudinal follow-up on FA
Two main reperfusion processes were identified after experimental RVO. Reperfusion of the
occluded blood vessel was the most common mechanism (Fig. 5A). Alternatively, collateral
vessels developed over time. These were usually present 7 days after the intervention (Fig. 5B)
and sometimes became more prominent after longer periods (e.g. 2 weeks in Fig. 5C). The ap-
pearance of these blood vessels was very similar to collaterals in humans (Fig. 5F). Interestingly,
the collaterals run in all three vascular plexuses[34] of the mouse retina (Fig. 5D, 5E: superficial
(dark green arrow), intermediate (green arrow), deep (light green arrow)).
VEGF
VEGF levels in the retina were 99.6±16.1 pg/ml for the CRVO group and 79.3±12.6 pg/ml for
the BRVO group at day 1, compared to 12.5±2.0 pg/ml in the control group (Fig. 6). On day 3
the VEGF levels had decreased to 28.5±6.5 pg/ml in the CRVO group and 17.2±8.3 pg/ml in
the BRVO group, respectively. Retinal VEGF levels were significantly different from those in
control eyes on day 1 (p<0.0001). The difference between the BRVO and the CRVO group was
not significant at these time points.
Discussion
In humans, the acute phase of partial or complete venous occlusion features ischemia, retinal
hemorrhages and edema in the neuroretina. The acute phase is followed by a protracted phase
dominated by remodeling of vessels and sometimes development of collateral venous drainage
bypassing the site of occlusion. The chronic phase is largely influenced by the degree of ische-
mia and ensuing complications such as neovascularization. We here present the clinical find-
ings in a highly reproducible mouse model of laser induced RVO. Depending on the number of
veins occluded by photothrombosis, the model either mimics the features of CRVO or BRVO.
Similar to RVO seen in humans, several stages can be differentiated in the mouse model: Im-
mediately following laser photocoagulation the venous blood flow is interrupted and the veins
become slightly dilated and tortuous. In the acute phase there is marked edema of the neurore-
tina as seen on OCT, followed by atrophy of the inner layers of the retina in the chronic phase.
In the current model we have not observed any new vessels, independently of the type of laser
application. This is in keeping with the findings reported by other groups[25,27]. Only in a sin-
gle paper on C57BL/6 were new vessels noted[27] in non-modified mice. In another paper new
vessels after experimental RVO in the mouse were only observed after durable hematopoietic
stem cell grafting[25]. Depending on the aims of the study, different strains of animals may be
angiogram. (K-O) Horizontal scans taken through the optic nerve head. (D, K, L) Hyperreflectivity with
washed-out retinal structures and thickening of the retina are observed within the first few days. (F-H,M-O)
Thereafter progressive thinning of the inner retinal layers is evident. (F) A sliver of subretinal fluid (yellow
arrows) is apparent [scale bars 200 μm].
doi:10.1371/journal.pone.0119046.g004
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Fig 5. Reperfusion patterns after single retinal vein occlusion. (A–C) Angiographic findings observed
7–14 days after experimental retinal vein occlusion are displayed. (A) Reperfusion had occurred in some
eyes at week one. (B, C) Collateral blood vessels were evident in others. (C) These collaterals observed in an
eye two weeks after experimental RVO were particularly prominent. (D, E) The optical coherence
tomography scans taken horizontally from this eye highlight the depth location of the different vascular
plexuses in the retina. While the normal major retinal veins (blue and dark green arrowhead) lie adjacent to
the inner limiting membrane, the collaterals, representing dilated preexisting blood vessels, are found deeper
in the retina (light green and green arrowhead in E). (F) Collateral blood vessels in a human with chronic
BRVO for comparison. The vein is blocked at an arterio-venous crossing (red arrow) and appears dilated
distal to the occlusion site. Tortuous collateral veins (yellow arrowhead) span from the dilated occluded vein
to a proximal venous branch.
doi:10.1371/journal.pone.0119046.g005
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favorable. The occlusion rate between pigmented and albino mice seems to be similar[35].
However, in pigmented mice more energy will be absorbed by the RPE and choroid, and the
rate of choroidal new vessel formation can be expected to be higher in pigmented animals.
We have performed FA with two different devices, namely an ultra-widefield system (Optos
200Tx) and confocal scanning laser ophthalmoscopy (Heidelberg Spectralis HRA). The latter
carries the advantage that it is possible to separately image the three vascular plexuses of the
mouse by focusing on the different layers[36]. A robust RVO mouse model may be helpful as
there is only limited knowledge of the cascade of events triggered at the cellular level after
RVO. As such this model is well suited to study the role of acute inflammatory mediators and
local immune cells such as microglia or invading macrophages. Not only has inflammation
been connected to thrombus formation[37], but it is even more instrumental in the self perpet-
uating cycle leading to establishment of chronic macular edema secondary to vein occlusion,
which can persist despite collateral formation and subsiding tissue hypoxia[38,39]. Inflamma-
tion together with increased intraluminal pressure favors leakage of serum proteins and aug-
mented oncotic pressure in the interstitium. This in turn further impairs capillary perfusion
and exacerbates hypoxia, boosting formation of VEGF and inflammatory cytokines[40]. The
success of intravitreal steroids for the treatment of macular edema secondary to RVO has
shown that inflammation is likely to play a major role in the chronic phases of this disease[14].
However, due to the side effects of this substance class, such as cataract formation or steroid in-
duced glaucoma, a more targeted drug against specific elements in the inflammatory cascade
following RVO would be desirable.
There are some limitations to the model presented in this paper. First, cystoid edema was
not observed in any of the experimental animals. In humans, leakage from vascular damage of
retinal vessel is thought to result mainly in cyst formation in the inner nuclear layers, whereas
outer blood-retinal barrier dysfunction is associated with cysts in the Henle fiber layer[41], and
sometimes subretinal fluid[42]. Muller cells have a central role in edema formation and can
Fig 6. Retinal vascular endothelial growth factor (VEGF) levels. Bar graph of retinal VEGF levels at day 1
and day 3 after experimental vein occlusion (values represent means±SEM, where n = 6 for controls and n =
3 for each experimental group at each time point, **** p< 0.0001). Retinal VEGF levels were raised relative
to controls on day 1, but the difference between the CRVOmodel and the BRVOmodel was not statistically
significant at any time point.
doi:10.1371/journal.pone.0119046.g006
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become swollen themselves[43]. The ‘Z-shaped’ morphology of Muller cells is characteristic for
the structure of the human fovea[41]. Rodents do not have a macula and lack the characteristic
features of the macula in man. The human macula is characterized by high cell density and
metabolic activity, and is therefore particularly predisposed for dysfunction if the metabolism
is compromised[44]. Furthermore, cyst formation might be a sign of chronicity. A healthy reti-
na can probably compensate for acute damage to the retinal vasculature. These are possible ex-
planations for the fact that we did not observe cystoid changes in edematous retinas after
experimental RVO. Another limitation of our model is that the laser spot itself may cause an
inflammatory response, which may in turn influence the course of RVO in the mouse.
Despite these limitations this model has several advantages. In the first instance, the same
imaging techniques as in humans, FA and OCT, can be used. This is to our knowledge the first
longitudinal quantification of retinal morphology in a mouse model of BRVO and CRVO
using spectral domain OCT. OCT allows a reliable quantification of retinal swelling and degen-
eration in the same mouse at different time points, offering an excellent in vivo readout for
therapeutic agents in preclinical studies. Models of RVO represent ideal tools to study ische-
mia-reperfusion injury of the central nervous system. The eye as an investigational organ has
several advantages over stroke models involving brain damage proper with ensuing morbidity
affecting the experimental animal. Due to the transparent nature of the ocular media the retina
can be observed in vivo in a longitudinal fashion. The neuronal cells in the retina are highly or-
ganized and systematic histological evaluation is straightforward.
The current model is not labor intensive, minimally invasive, and does not cause any sys-
temic side effects or morbidity to the mice. Drug delivery is possible via intravitreal administra-
tion and not restricted to systemic application. The degree of ischemia is highly reproducible
because the catchment area of the individual veins is relatively constant.
Supporting Information
S1 Fig. Cell density in the ganglion cell layer and thickness of the inner nuclear layer in
mouse eyes with experimental central retinal vein occlusion. The reduction of the cell densi-
ty in the ganglion cell layer was 45% (p< 0.0001; n = 6) compared to control eyes (n = 3). The
decrease in thickness of the inner nuclear layer was of similar magnitude (47%, p< 0.0001).
(TIF)
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